|
APLS | Apellis Pharmaceuticals, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.16 |
| Leverage | 62.11% |
| Market Cap | $ 2.5B |
| PE | 58.93 |
| Dividend Yield | 0.00% |
| Profit | $ 42.4m |
| Margin | 4.20% |
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.